Telomir Pharmaceuticals Files 8-K
Ticker: TELO · Form: 8-K · Filed: May 29, 2025 · CIK: 1971532
Sentiment: neutral
Topics: 8-K, disclosure, pharmaceuticals
TL;DR
Telomir Pharma (TELO) filed a routine 8-K, confirming Miami HQ. No major news yet.
AI Summary
On May 29, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is located in Miami, Florida, and operates within the Pharmaceutical Preparations industry. No specific material events or financial transactions were detailed in the provided excerpt.
Why It Matters
This filing serves as a notification to the SEC and investors about the company's operational status and location. It is a standard disclosure requirement for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard procedural disclosure and does not contain information about significant financial events, risks, or strategic changes.
Key Players & Entities
- Telomir Pharmaceuticals, Inc. (company) — Registrant
- Miami, Florida (location) — Principal Executive Offices
- May 29, 2025 (date) — Date of earliest event reported
FAQ
What is the primary business of Telomir Pharmaceuticals, Inc.?
Telomir Pharmaceuticals, Inc. operates in the Pharmaceutical Preparations industry, as indicated by its Standard Industrial Classification code [2834].
Where are Telomir Pharmaceuticals, Inc.'s principal executive offices located?
The principal executive offices of Telomir Pharmaceuticals, Inc. are located at 100 SE 2nd St, Suite 2000, #1009, Miami, Florida.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is May 29, 2025.
What is the company's telephone number?
The registrant's telephone number, including area code, is (786) 396-6723.
What is the Commission File Number for Telomir Pharmaceuticals, Inc.?
The Commission File Number for Telomir Pharmaceuticals, Inc. is 001-41952.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 29, 2025 regarding Telomir Pharmaceuticals, Inc. (TELO).